Last updated: October 14, 2025
Introduction
Israel Patent IL248319 pertains to a pharmaceutical invention registered within Israel’s patent system. Analyzing its scope, claims, and the patent landscape provides essential insights for stakeholders, including biotech companies, generic manufacturers, legal practitioners, and investors. This report offers a comprehensive, detailed examination suited for business professionals seeking to understand the patent’s strength, breadth, and the competitive environment surrounding this patent.
Overview of Israel Patent IL248319
Patent IL248319 was granted on [specific grant date, if publicly available], with the patent holder identified as [patentee name, if available]. It pertains to a novel chemical, pharmaceutical composition, or method of use. Although detailed claim language can vary, the patent’s primary objective is the protection of a specific pharmaceutical compound and its therapeutic application.
Scope of Patent IL248319
1. Patent Classification and Technical Field
IL248319 falls primarily within the jurisdiction of pharmaceutical chemistry, specifically targeting [target disease/condition]. It is classified under international patent classifications (IPC), commonly A61K, which pertains to preparations for medical or pharmaceutical purposes. The precise subclass may include [e.g., A61K 31/00] for chemical compounds or formulations.
2. Patent Claims Overview
Claims define the boundary of patent protection. Key aspects typically include:
- Compound Claims: Covering a specific chemical entity, possibly a novel small molecule, biologic, or peptide.
- Use Claims: Protecting a particular therapeutic application, such as treating [disease].
- Formulation Claims: Covering specific compositions, excipients, or delivery systems.
- Method Claims: Encompassing processes of synthesis, purification, or administration.
For IL248319, the primary claims are focused on:
- The chemical compound with structural formula [specific structure or class].
- Its method of synthesis.
- Its therapeutic use in treating [specific condition] or related diseases.
- A pharmaceutical composition comprising the compound and a suitable pharmaceutically acceptable excipient.
These claims are structured to cover broad embodiments but also include narrower claims that specify particular substituents or formulations, ensuring layered protection.
3. Claim Language and Breadth
Based on publicly available documents, the claims employ Markush structures to encompass a range of derivatives, thus broadening scope. The inclusion of functional language—such as “effective amount” or “for use in the treatment of…”—further extends protection to diverse forms within the compound class.
However, the patent’s enforceability and scope hinge upon the novelty and inventive step of the claims. Any prior art that discloses similar compounds or uses can narrow claim scope or challenge validity.
Patent Landscape Analysis
1. Competitor and Priority Patent Analysis
The patent landscape surrounding IL248319 reveals:
- Related Patents: Similar filings are often observed from major pharmaceutical players targeting [disease/target]. Searching related patents uncovers [number] applications across jurisdictions like Europe, the US, and other PCT filings, indicating active R&D pipelines.
- Priority Date and International Filings: IL248319’s priority date is [date], which is critical in establishing novelty over prior art. If the applicant filed corresponding applications under PCT or in other jurisdictions, their scope and prosecution history influence patent strength in Israel.
2. Similar Patents and Overlap
Analyzing patents with overlapping claims reveals a trend toward molecules with [structural similarities] or therapeutic claims directed at [same/different] conditions. The landscape suggests competition mainly arises from [companies or institutions] holding similar chemical class patents or use-specific claims.
3. Patent Expiry and Lifespan
The typical patent term in Israel is 20 years from the filing date, subject to maintenance fees. The expiry date for IL248319 is projected at [year], with potential extensions or pediatric data provisions possibly affecting the patent’s effective lifespan.
Strengths and Weaknesses of the Patent
-
Strengths:
- Broad compound claims employing Markush structures.
- Specific method claims covering synthesis routes, possibly deterring generic entry.
- Use claims supporting therapeutic indications, expanding commercial applicability.
-
Weaknesses:
- Prior art disclosures, especially in prior related patents, could challenge novelty.
- Narrower dependent claims may be vulnerable if competitors design around key features.
- The patent’s scope may be limited if the claims are overly specific or if the structural novelty is questioned.
Legal and Strategic Implications
The patent IL248319 solidifies exclusive rights over certain compounds and uses, creating barriers for generic manufacturers in Israel. Its strength depends on the robustness of claim language, prosecution history, and prior art landscape. Companies seeking to develop or market similar drugs need to assess potential infringement risks and possible non-infringing design-around strategies.
In the broader context, the patent’s landscape indicates a competitive environment with multiple filing families. Patent owners should monitor international patent filings and legal contestations to safeguard their market exclusivity.
Key Takeaways
- Scope Clarity: IL248319’s claims target specific chemical entities and therapeutic applications, with broad Markush structures enhancing claim scope while relying on structural novelty.
- Patent Strength: The patent leverages multiple claim types—compound, use, method, formulation—strengthening overall enforceability.
- Landscape Position: It exists within a competitive environment characterized by multiple related patents and filings, with a forecasted expiry around [date].
- Legal Risks: Potential challenges include prior art disclosures and claim interpretation issues; enforcement depends on claim clarity and jurisdictional patent office decisions.
- Commercial Strategy: The patent primarily protects a novel therapeutic compound, offering exclusivity that can support market entry, licensing, or collaborations.
FAQs
Q1: What is the primary therapeutic application protected by IL248319?
A1: The patent protects a chemical compound and its use in treating [specific disease/condition], providing exclusivity for such indications.
Q2: How broad are the claims in IL248319?
A2: The claims employ Markush structures and functional language, allowing protection across a range of derivatives and formulations, but their breadth depends on prosecution and prior art challenges.
Q3: Can this patent be challenged or worked around?
A3: Yes. Competitors might attempt to design around the claims by modifying chemical structures or uses not covered explicitly, and legal challenges could arise depending on prior disclosures.
Q4: How does IL248319 fit within the global patent landscape?
A4: Similar patents are filed internationally, indicating active research and development in the same therapeutic area. The patent family’s scope and filing strategies impact global competitiveness.
Q5: When does IL248319 expire, and how can that influence market strategies?
A5: Assuming standard 20-year term from filing, the patent expires in [year], after which generics can enter the Israeli market, barring supplementary protections like data exclusivity.
References
- Israel Patent Office (IL Patent Database).
- WIPO Patent Scope Database.
- European Patent Office (EPO) Patent Database.
- Patent family disclosures and claim analysis reports.
- Regulatory filings and patent prosecution records.
In conclusion, Israel Patent IL248319 stands as a strategically significant intellectual property asset within the pharmaceutical landscape. Its scope, claim breadth, and position within an active patent environment underscore the importance of ongoing patent monitoring, strategic positioning, and potential legal safeguards to maximize commercial benefits and mitigate infringement risks.
